
|Articles|August 4, 2019
Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology
Author(s)Julianne Mobilian
ICYMI: Here's what's in the 2019 pipeline
Advertisement
Rajesh Rajpal, MD, Chief Medical Officer of Avedro, Inc., provides a company update on Epi-on crosslinking (CXL) and PiXL technology during the 2019 ASCRS conference in San Diego.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
2
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
3
Alcon raises offer in amended deal to acquire STAAR Surgical
4
Neurotrophic keratitis outcomes improve with early, stage-based care
5













































.png)


